Shenzhen New Industries Biomedical Engineering (300832) Q4 2024 earnings summary

Executive summary

• Achieved 15.41% year-over-year revenue growth to ¥4,535.4 million in 2024.

• Net profit attributable to shareholders rose 10.57% year-over-year to ¥1,828.5 million.

• Continued innovation with new product launches and expanded service to large medical clients.

Financial highlights

• Operating profit increased 11.38% year-over-year to ¥2,111.2 million.

• Total assets grew 16.99% to ¥9,619.5 million at year-end.

• Net cash flow from operating activities decreased 4.36% year-over-year.

• Basic EPS rose 10.53% to ¥2.3271.

Outlook and guidance

• Plans to deepen overseas market strategy and enhance global competitiveness.

• Expects continued limited impact from US tariff policy due to minimal US revenue exposure.